| Neuromodulation in Depressed and Schizophrenic Patients - Changing MEP (Muscle Evoked Potentials) by tDCS (Transcranial Direct Current Stimulation) (NCT01150734) | Ludwig-Maximilians - University of Munich | 2009-10-01 |
| A Study of Olanzapine in Patients With Schizophrenia (NCT00970281) | Eli Lilly and Company | 2009-09-01 |
| Metacognitive Training in Schizophrenia (NCT01029067) | Universitätsklinikum Hamburg-Eppendorf | 2009-09-01 |
| Clinical Risk State for Bipolar Disorder in Adolescents (NCT01383915) | Northwell Health | 2009-09-01 |
| An Open Trial of Cysteamine Treatment in Schizophrenia (NCT01139125) | Augusta University | 2009-09-01 |
| L-arginine in Treatment as Usual in Schizophrenia (NCT00718510) | University of Alberta | 2009-09-01 |
| Epidemiology of Schizophrenia in Bulgaria (NCT00984373) | AstraZeneca | 2009-09-01 |
| Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia (NCT00981123) | AstraZeneca | 2009-09-01 |
| Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI (NCT02334280) | Dartmouth-Hitchcock Medical Center | 2009-09-01 |
| Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects (NCT01090440) | GlaxoSmithKline | 2009-09-01 |
| Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia (NCT00954122) | AstraZeneca | 2009-09-01 |
| Study in Adolescents With Schizophrenia or Bipolar Disorder (NCT00982020) | Eli Lilly and Company | 2009-09-01 |
| A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls (NCT00934635) | Janssen-Cilag G.m.b.H | 2009-09-01 |
| Cognitive Remediation in Early Phase Psychosis (NCT01546467) | Oslo University Hospital | 2009-09-01 |
| Risk Perception in Drug-Dependent Adults With and Without Schizophrenia (NCT01031563) | National Institute on Drug Abuse (NIDA) | 2009-08-18 |
| Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia (NCT01010477) | Rutgers, The State University of New Jersey | 2009-08-01 |
| Metabolic Syndrome in Patients With First-episode Schizophrenia (NCT00957294) | Aarhus University Hospital | 2009-08-01 |
| D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia (NCT00963924) | Massachusetts General Hospital | 2009-08-01 |
| Multicenter, Open-label, Safety and Tolerability Study (NCT01649557) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2009-08-01 |
| Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants (NCT01387542) | Janssen-Cilag Ltd.,Thailand | 2009-08-01 |
| Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia (NCT00864825) | Sheba Medical Center | 2009-08-01 |
| Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs (NCT01479413) | Chang Gung Memorial Hospital | 2009-08-01 |
| Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine (NCT01047215) | Taichung Veterans General Hospital | 2009-08-01 |
| The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients (NCT01137799) | Janssen Pharmaceutica N.V., Belgium | 2009-08-01 |
| A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended (NCT00922090) | AstraZeneca | 2009-07-01 |
| Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia (NCT00833976) | Massachusetts General Hospital | 2009-07-01 |
| A Repeat Dose Positron Emission Tomography Study With GSK1144814 (NCT01209039) | GlaxoSmithKline | 2009-07-01 |
| Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan (NCT01077687) | National Taiwan University Hospital | 2009-07-01 |
| Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning (NCT00937261) | University of California, Irvine | 2009-07-01 |
| Once Weekly D-cycloserine for Schizophrenia (NCT00964041) | Massachusetts General Hospital | 2009-07-01 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia (NCT00905307) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2009-07-01 |
| Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER (NCT02075528) | Taipei City Hospital | 2009-07-01 |
| Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network (NCT00930150) | National Institute of Mental Health (NIMH) | 2009-07-01 |
| Extended Specialized Assertive Intervention for First Episode Psychosis (NCT00914238) | University of Copenhagen | 2009-07-01 |
| Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia (NCT01034085) | National Institute on Drug Abuse (NIDA) | 2009-06-02 |
| InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics (NCT01026285) | Janssen-Cilag International NV | 2009-06-01 |
| Vitamin D Supplementation in Psychiatric Illnesses (NCT01004354) | University of Massachusetts, Worcester | 2009-06-01 |
| Arithmetic Training With the Kumon Method for Cognition in Schizophrenia (NCT03055520) | University of Sao Paulo | 2009-06-01 |
| Open-label Study of Curcumin C-3 Complex in Schizophrenia (NCT01875822) | Woodbury, Michel, M.D. | 2009-06-01 |
| Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders (NCT00914030) | University Hospital, Strasbourg, France | 2009-06-01 |
| Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients (NCT00921804) | AstraZeneca | 2009-06-01 |
| Role of Anti-Inflammatory Agents in Patients With Schizophrenia (NCT00929955) | Pakistan Institute of Living and Learning | 2009-06-01 |
| 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years (NCT00946985) | Ortho-McNeil Janssen Scientific Affairs, LLC | 2009-06-01 |
| Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia (NCT00894842) | National Research Foundation, Singapore | 2009-06-01 |
| Oculomotor and Spatial Cognition Deficits in Schizophrenia (NCT00931996) | University of Illinois at Chicago | 2009-06-01 |
| Polypharmacy in Clozapine-resistant Schizophrenia (NCT00918021) | Niuvanniemi Hospital | 2009-06-01 |
| Serum Clozapine and Cognition (NCT00951418) | University of Aarhus | 2009-06-01 |
| Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls (NCT01214005) | Brown University | 2009-06-01 |
| Biomarkers in Schizophrenia (NCT00817336) | Nathan Kline Institute for Psychiatric Research | 2009-06-01 |
| A Study of Cariprazine in Patients With Chronic Stable Schizophrenia (NCT00839852) | Forest Laboratories | 2009-05-31 |
| Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome (NCT01714011) | University of Malaya | 2009-05-01 |
| Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder (NCT00892021) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-05-01 |
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients (NCT01043250) | Samsung Medical Center | 2009-05-01 |
| A Shared Decision Making Training for Inpatients With Schizophrenia (NCT00885716) | Technical University of Munich | 2009-05-01 |
| A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia (NCT00915512) | Janssen-Cilag Turkey | 2009-05-01 |
| A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia (NCT01942382) | Janssen Pharmaceutical K.K. | 2009-04-01 |
| Add On Treatment for Cognitive Deficits in Schizophrenia (NCT01346163) | University of Pennsylvania | 2009-04-01 |
| Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia (NCT00876304) | Taisho Pharmaceutical Co., Ltd. | 2009-04-01 |
| Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA) (NCT00885690) | University of Aarhus | 2009-04-01 |
| Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia (NCT00873249) | AstraZeneca | 2009-04-01 |
| Cognitive-Behavioral Therapy in Veterans With Schizophrenia (NCT00688259) | VA Office of Research and Development | 2009-04-01 |
| Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients (NCT00882518) | AstraZeneca | 2009-04-01 |
| Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine (NCT00934908) | Medical University of South Carolina | 2009-03-01 |
| Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia (NCT00847600) | Sha'ar Menashe Mental Health Center | 2009-03-01 |
| Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on Treatments (NCT00894296) | Shalvata Mental Health Center | 2009-03-01 |
| Subjective Well Being of Schizophrenic Patients in Greece (NCT00857064) | AstraZeneca | 2009-03-01 |
| A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia (NCT00743847) | Pfizer | 2009-03-01 |
| A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients (NCT00845026) | Denovo Biopharma LLC | 2009-03-01 |
| Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia (NCT00981526) | University of Massachusetts, Worcester | 2009-03-01 |
| A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations (NCT01075373) | National Taiwan University Hospital | 2009-03-01 |
| A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) (NCT00827918) | Merck Sharp & Dohme LLC | 2009-03-01 |
| Effects of Delta-9-THC and Iomazenil in Healthy Humans (NCT00982982) | Yale University | 2009-02-11 |
| Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia (NCT00870909) | Hôpital le Vinatier | 2009-02-02 |
| NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia (NCT00833456) | AstraZeneca | 2009-02-01 |
| A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder (NCT01094249) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-02-01 |
| Seroquel XR in Adults With Schizophrenia (NCT00852631) | AstraZeneca | 2009-02-01 |
| Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia (NCT00588731) | Yale University | 2009-02-01 |
| Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia (NCT01279213) | Universidad Nacional de Rosario | 2009-01-01 |
| The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study) (NCT00816907) | National Institute of Mental Health (NIMH) | 2009-01-01 |
| D-serine Monotherapy for Schizophrenia (NCT00816894) | Herzog Hospital | 2009-01-01 |
| Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing (NCT01602263) | Johns Hopkins University | 2009-01-01 |
| Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia (NCT01055509) | University of Southern Denmark | 2009-01-01 |
| Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years (NCT01362439) | Janssen-Cilag S.p.A. | 2009-01-01 |
| 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study (NCT00818298) | Centre for Addiction and Mental Health | 2009-01-01 |
| Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia (NCT00825539) | Novartis Pharmaceuticals | 2009-01-01 |
| Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment (NCT00789022) | Shalvata Mental Health Center | 2009-01-01 |
| Study of Mental Care in Spain (NCT00824031) | AstraZeneca | 2009-01-01 |
| Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients (NCT00781794) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-01-01 |
| A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men (NCT01060228) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-01-01 |
| Shiatsu Adjuvant Therapy And Placebo For Schizophrenia (NCT00788970) | Herzog Hospital | 2009-01-01 |
| Clinical Benefits of Seroquel XR in Anxiety Disorder (NCT01672554) | Corporation de Recherche en Neuropsycho Pharmacologie de Quebec | 2008-12-01 |
| Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712 (NCT00805454) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2008-12-01 |
| A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia (NCT00817648) | Shanghai Mental Health Center | 2008-12-01 |
| Specific Cognitive Remediation for Schizophrenia (NCT01607424) | Hôpital le Vinatier | 2008-12-01 |
| Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia (NCT00793780) | Yale University | 2008-12-01 |
| rTMS Effects on Smoking Cessation and Cognition in Schizophrenia (NCT00736710) | Centre for Addiction and Mental Health | 2008-12-01 |
| Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS) (NCT01154829) | University of Copenhagen | 2008-12-01 |
| Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment (NCT00809731) | AstraZeneca | 2008-12-01 |
| Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia (NCT00821600) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-12-01 |
| Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia (NCT00825045) | Centre for Addiction and Mental Health | 2008-12-01 |